These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24847966)

  • 1. The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide.
    Devoe CE; Li JY; Demopoulos AM
    J Neurooncol; 2014 Aug; 119(1):217-20. PubMed ID: 24847966
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
    Houillier C; Choquet S; Touitou V; Martin-Duverneuil N; Navarro S; Mokhtari K; Soussain C; Hoang-Xuan K
    Neurology; 2015 Jan; 84(3):325-6. PubMed ID: 25527263
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenalidomide for mantle cell lymphoma.
    Skarbnik AP; Goy AH
    Expert Rev Hematol; 2015 Jun; 8(3):257-64. PubMed ID: 25952533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematological cancers: Lenalidomide--SPRINT to a new standard?
    Hutchinson L
    Nat Rev Clin Oncol; 2016 Apr; 13(4):204. PubMed ID: 26925960
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Desensitization to lenalidomide].
    Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME
    Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.
    Dreicer R
    Curr Oncol Rep; 2007 Mar; 9(2):120-3. PubMed ID: 17288877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide as first-line therapy for elderly CLL patients.
    Gilbert JA
    Lancet Oncol; 2013 Aug; 14(9):e345. PubMed ID: 24058966
    [No Abstract]   [Full Text] [Related]  

  • 10. [Papular drug eruption along the lines of Blaschko caused by lenalidomide].
    Grape J; Frosch P
    Hautarzt; 2011 Aug; 62(8):618-20. PubMed ID: 21445702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness.
    Paumgartten FJ
    Cad Saude Publica; 2014 Apr; 30(4):684-6. PubMed ID: 24896044
    [No Abstract]   [Full Text] [Related]  

  • 12. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
    Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
    Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide.
    Schuelper N; Flohr A; Trümper L; Wulf GG
    Ann Hematol; 2014 Nov; 93(11):1929-30. PubMed ID: 24711172
    [No Abstract]   [Full Text] [Related]  

  • 15. New agents and new end points for recurrent gliomas.
    Brandes AA; Franceschi E
    J Clin Oncol; 2011 Mar; 29(9):e245-6; author reply e247. PubMed ID: 21282544
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
    Giglio P; Dhamne M; Hess KR; Gilbert MR; Groves MD; Levin VA; Kang SL; Ictech SE; Liu V; Colman H; Conrad CA; Loghin M; de Groot J; Yung WK; Puduvalli VK
    Cancer; 2012 Jul; 118(14):3599-606. PubMed ID: 22086614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in relapsed refractory non-Hodgkin's lymphoma: An Indian perspective.
    Lakshmaiah KC; Rachan Shetty KS; Sathyanarayanan V; Lokanatha D; Abraham LJ; Babu KG
    J Cancer Res Ther; 2015; 11(4):857-61. PubMed ID: 26881531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alfa-2a in recurrent metastatic hemangiopericytoma.
    Lackner H; Urban C; Dornbusch HJ; Schwinger W; Kerbl R; Sovinz P
    Med Pediatr Oncol; 2003 Mar; 40(3):192-4. PubMed ID: 12518351
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.
    Lestang E; Caristan A; Néel A; Graveleau J; Duhamel E; Masseau A; Connault J; Maisonneuve H; Le Gouill S; Blin N; Touzeau C; Moreau P; Hamidou M
    Leuk Lymphoma; 2015 Jun; 56(6):1895-6. PubMed ID: 25347429
    [No Abstract]   [Full Text] [Related]  

  • 20. Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
    Nakazato T; Mihara A; Ito C; Sanada Y; Aisa Y
    Ann Hematol; 2012 Mar; 91(3):473-4. PubMed ID: 21647581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.